카페시타빈 시장 : 적응증별, 약물 유형별, 최종사용자별 - 세계 기회 분석 및 산업 예측(2024-2033년)

Capecitabine Market By Indication (Colorectal Cancer, Breast Cancer, Others) , By Drug Type (Branded, Generic) By End User (Hospitals, Homecare, Specialty Clinics, Others) : Global Opportunity Analysis and Industry Forecast, 2024-2033

US $ 4,425 ￦ 6,174,000

PDF (Business License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄는 5회 가능하며, 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다. 2명 이상이 이용할 경우, 추가 요금을 지불하여 라이선스 업그레이드로 최대 5명까지 이용 가능합니다.

US $ 7,412 ￦ 10,342,000

PDF (Enterprise User License) & Excel (Data Pack) & Free Update

PDF 보고서 및 Excel 데이터를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다. 보고서 업데이트 서비스가 무료로 제공됩니다.

한글목차

세계 카페시타빈 시장은 2023년 4억 달러로 평가되며, 2024-2033년 연평균 5%의 성장률을 기록하며 2033년에는 7억 달러에 달할 것으로 예상됩니다.

카페시타빈은 유방암, 대장암, 직장암 등 다양한 암 치료에 사용되는 경구용 화학요법제입니다. 카페시타빈은 대사 길항제로 알려진 약물의 일종으로, 암세포의 증식과 전이를 억제하여 효과를 발휘합니다. 카페시타빈은 프로드러그(prodrug)로 체내에서 활성형인 5-플루오로우라실(5-FU)로 전환됩니다. 일단 전환되면 5-FU는 암세포의 DNA와 RNA 합성을 억제하여 암세포를 사멸시킵니다. 기존의 화학요법제가 정맥으로 투여하는 반면, 카페시타빈은 경구용이며, 보통 정제 형태로 복용합니다. 이 때문에 환자에게 편리하고 많은 경우 외래에서 치료할 수 있습니다.

카페시타빈 시장의 성장을 주도하는 것은 암 유병률의 증가입니다. 전 세계적으로 암 환자 수가 증가함에 따라 효과적인 치료 옵션에 대한 수요가 급증하고 있습니다. 또한, 노인 인구의 증가는 카페시타빈 시장의 중요한 촉진요인으로 부상하고 있습니다. 나이가 들면 유전자 돌연변이 축적, 면역체계 약화, 평생 발암물질에 장기간 노출되는 등의 요인으로 인해 암에 걸릴 확률이 높아집니다. 이러한 고령화 사회로의 인구통계학적 변화는 고령자의 암 진단 유병률 증가로 이어져 카페시타빈과 같은 효과적인 암 치료제에 대한 수요를 증가시키고 있습니다.

그러나 빈혈, 흉부 불편감, 구토, 혈액 응고 장애 등 카페시타빈과 관련된 부작용이 시장 성장을 저해하고 있습니다. 한편, 제품 혁신, 출시 및 시장 다각화는 시장 진입 기업에게 유리한 기회를 제공합니다. 예를 들어, 2022년 12월 실파 메디케어(Shilpa Medicare Ltd.)는 90초 이내 고속 분산 기술을 적용한 카페시타빈 1,000MG 분산 정제를 출시할 예정이라고 발표했습니다. 이 제품은 필요한 과학적 증명과 생물학적 동등성 비교시험을 통해 입증되었으며, 인도에서 의료제품의 안전성, 유효성 및 품질을 보장하는 인도의 국가 규제기관(NRA)인 중앙의약품표준관리기구(CDSCO)의 승인을 받았습니다. 이 제품은 대장암과 전이성 유방암 치료에 사용됩니다.

부문 개요

세계 카페시타빈 시장은 적응증, 약물 유형, 최종사용자, 지역으로 구분됩니다. 적응증별로는 대장암, 유방암, 기타로 나뉩니다. 약물 유형별로는 브랜드 의약품과 제네릭 의약품으로 분류됩니다. 최종사용자별로는 병원, 재택의료, 전문센터, 기타로 분류됩니다. 지역별로는 북미, 유럽, 아시아태평양, 라틴아메리카, 중동 및 아프리카로 분석됩니다.

주요 조사 결과

적응증별로는 유방암 부문이 2023년 시장 최대 주주였습니다.

약물 유형별로는 브랜드 부문이 2023년 가장 높은 시장 점유율을 차지했습니다.

최종사용자별로는 병원 부문이 2023년 가장 큰 점유율을 차지했습니다.

지역별로는 북미가 2023년 카페시타빈 시장을 주도했습니다.

경쟁 시나리오

이 보고서는 사용자 정의가 가능합니다.

• 규제 가이드라인
• 고객의 관심사에 따른 기업 프로파일 추가
• 국가별 또는 지역별 추가 분석 - 시장 규모 및 전망
• 기업 개요 확대 목록
• 과거 시장 데이터
• 주요 진입기업 세부 정보(위치, 연락처, 공급업체/벤더 네트워크 등 포함, 엑셀 형식)

목차

제1장 소개

제2장 주요 요약

제3장 시장 상황

• 시장 정의와 범위
• 주요 조사 결과
  • 주요 투자 기회
  • 주요 성공 전략
• Porter's Five Forces 분석
• 시장 역학
  • 성장 촉진요인
  • 성장 억제요인
  • 기회

제4장 카페시타빈 시장 : 적응증별

• 시장 개요
• 대장암
• 유방암
• 기타

제5장 카페시타빈 시장 : 약물 유형별

• 시장 개요
• 브랜드
• 제네릭

제6장 카페시타빈 시장 : 최종사용자별

• 시장 개요
• 병원
• 재택의료
• 전문 클리닉
• 기타

제7장 카페시타빈 시장 : 지역별

• 시장 개요
• 북미
  • 주요 시장 동향과 기회
  • 미국의 카페시타빈 시장
  • 캐나다의 카페시타빈 시장
  • 멕시코의 카페시타빈 시장
• 유럽
  • 주요 시장 동향과 기회
  • 독일의 카페시타빈 시장
  • 프랑스의 카페시타빈 시장
  • 영국의 카페시타빈 시장
  • 이탈리아의카페시타빈 시장
  • 스페인의 카페시타빈 시장
  • 기타 유럽의 카페시타빈 시장
• 아시아태평양
  • 주요 시장 동향과 기회
  • 일본의 카페시타빈 시장
  • 중국의 카페시타빈 시장
  • 호주의 카페시타빈 시장
  • 인도의 카페시타빈 시장
  • 한국의 카페시타빈 시장
  • 기타 아시아태평양의 카페시타빈 시장
• 라틴아메리카, 중동 및 아프리카
  • 주요 시장 동향과 기회
  • 브라질의 카페시타빈 시장
  • 사우디아라비아의 카페시타빈 시장
  • 남아프리카공화국의 카페시타빈 시장
  • 기타 라틴아메리카, 중동 및 아프리카의 카페시타빈 시장

제8장 경쟁 상황

• 소개
• 주요 성공 전략
• 주요 10개 기업 제품 매핑
• 경쟁 대시보드
• 경쟁 히트맵
• 주요 기업의 포지셔닝(2023년)

제9장 기업 개요

• F. Hoffmann-La Roche Ltd.
• Mylan N.V.
• Teva Pharmaceutical Industries Ltd.
• Sanofi
• Pfizer Inc.
• Dr. Reddy's Laboratories Ltd.
• Novartis AG
• Bayer AG
• Eli Lilly And Company.
• Merck And Co., Inc.

ksm

영문 목차

영문목차

The global capecitabine market was valued at $0.4 billion in 2023, and is projected to reach $0.7 billion by 2033, growing at a CAGR of 5% from 2024 to 2033.

Capecitabine is an oral chemotherapy medication used in the treatment of various cancers, including breast, colon, and rectal cancers. It belongs to a class of drugs known as antimetabolites, which work by interfering with the growth and spread of cancer cells. Capecitabine is a prodrug, meaning it is converted into its active form, 5-fluorouracil (5-FU), in the body. Once converted, 5-FU inhibits the synthesis of DNA and RNA in cancer cells, leading to their death. Traditional chemotherapy drugs administered intravenously, whereas capecitabine is taken orally, usually in the form of tablets. This offers convenience to patients and allows for outpatient treatment in many cases.

The growth of the capecitabine market is driven by rise in the prevalence of cancer. With the growing number of cancer patients globally, there is surge in demand for the effective treatment option. Moreover, rise in geriatric population has emerged as a significant driver of the capecitabine market. As individuals age, they become more susceptible to developing cancer due to factors such as accumulated genetic mutations, weakened immune systems, and prolonged exposure to carcinogens over their lifetime. This demographic shift toward an aging population has led to a higher prevalence of cancer diagnoses among older adults, creating a greater demand for effective cancer treatments such as capecitabine.

However, adverse effects related to capecitabine, such as anemia, chest discomfort, vomiting, and blood clotting disorders, hamper the growth of the market. On the other hand, product innovation, launches, and diversification present lucrative opportunities for the market players. For instance, in December 2022, Shilpa Medicare Ltd. announced the launch of the Capecitabine 1000 MG dispersible tablet with novel technology of faster dispersion within 90 seconds. The product is supported by required scientific proof and comparative bioequivalence studies and is approved by Central Drugs Standard Control Organisation (CDSCO) -the National Regulatory Authority (NRA) of India, responsible for ensuring the safety, efficacy, and quality of medical products in the country. The product is used for treatment of colorectal and metastatic breast cancer.

Segmentation Overview

The global capecitabine market is segmented into indication, drug type, end user, and region. By indication, the market is divided into colorectal cancer, breast cancer, and others. Depending on drug type, it is categorized into branded and generic. According to end user, the market is classified into hospitals, homecare, specialty centers, and others. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Key Findings

By indication, the breast cancer segment was the largest shareholder in the market in 2023.

Depending on drug type, the branded segment held the highest market share in 2023.

According to end user, the hospitals segment accounted for the maximum share of the market in 2023.

Region wise, North America dominated the capecitabine market in 2023.

Competitive Scenario

The major players operating in the capecitabine market include F. Hoffmann-La Roche Ltd., Mylan N.V, Teva Pharmaceutical Industries Ltd., Sanofi, Pfizer Inc., Dr. Reddy's Laboratories Ltd., Novartis AG, Bayer AG, Eli Lilly and Company, and Merck & Co., Inc. Other players in the market include GlaxoSmithKline Pharmaceuticals, Sun Pharmaceutical Industries Ltd, Aurobindo Pharma, Lupin, and Alkem Labs Ltd. These players have adopted several strategies, including product diversification & innovation, mergers & acquisitions, and collaborations to maintain their foothold in the market.

Additional benefits you will get with this purchase are:

• Quarterly Update and* (only available with a corporate license, on listed price)
• 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
• Free Upcoming Version on the Purchase of Five and Enterprise User License.
• 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
• 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
• Free data Pack on the Five and Enterprise User License. (Excel version of the report)
• Free Updated report if the report is 6-12 months old or older.
• 24-hour priority response*
• Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)

• Regulatory Guidelines
• Additional company profiles with specific to client's interest
• Additional country or region analysis- market size and forecast
• Expanded list for Company Profiles
• Historic market data
• Key player details (including location, contact details, supplier/vendor network etc. in excel format)

Key Market Segments

By Indication

• Colorectal Cancer
• Breast Cancer
• Others

By Drug Type

• Branded
• Generic

By End User

• Hospitals
• Homecare
• Specialty Clinics
• Others

By Region

• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Rest of Europe
• Asia-Pacific
  • Japan
  • China
  • Australia
  • India
  • South Korea
  • Rest of Asia-Pacific
• LAMEA
  • Brazil
  • Saudi Arabia
  • South Africa
  • Rest of LAMEA

Key Market Players:

• F. Hoffmann-La Roche Ltd.
• Mylan N.V.
• Teva Pharmaceutical Industries Ltd.
• Sanofi
• Pfizer Inc.
• Dr. Reddy's Laboratories Ltd.
• Novartis AG
• Bayer AG
• Eli Lilly and Company.
• Merck & Co., Inc.

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

• 1.1. Report Description
• 1.2. Key Market Segments
• 1.3. Key Benefits
• 1.4. Research Methodology
  • 1.4.1. Primary Research
  • 1.4.2. Secondary Research
  • 1.4.3. Analyst Tools and Models

CHAPTER 2: EXECUTIVE SUMMARY

• 2.1. CXO Perspective

CHAPTER 3: MARKET LANDSCAPE

• 3.1. Market Definition and Scope
• 3.2. Key Findings
  • 3.2.1. Top Investment Pockets
  • 3.2.2. Top Winning Strategies
• 3.3. Porter's Five Forces Analysis
  • 3.3.1. Bargaining Power of Suppliers
  • 3.3.2. Threat of New Entrants
  • 3.3.3. Threat of Substitutes
  • 3.3.4. Competitive Rivalry
  • 3.3.5. Bargaining Power among Buyers
• 3.4. Market Dynamics
  • 3.4.1. Drivers
  • 3.4.2. Restraints
  • 3.4.3. Opportunities

CHAPTER 4: CAPECITABINE MARKET, BY INDICATION

• 4.1. Market Overview
  • 4.1.1 Market Size and Forecast, By Indication
• 4.2. Colorectal Cancer
  • 4.2.1. Key Market Trends, Growth Factors and Opportunities
  • 4.2.2. Market Size and Forecast, By Region
  • 4.2.3. Market Share Analysis, By Country
• 4.3. Breast Cancer
  • 4.3.1. Key Market Trends, Growth Factors and Opportunities
  • 4.3.2. Market Size and Forecast, By Region
  • 4.3.3. Market Share Analysis, By Country
• 4.4. Others
  • 4.4.1. Key Market Trends, Growth Factors and Opportunities
  • 4.4.2. Market Size and Forecast, By Region
  • 4.4.3. Market Share Analysis, By Country

CHAPTER 5: CAPECITABINE MARKET, BY DRUG TYPE

• 5.1. Market Overview
  • 5.1.1 Market Size and Forecast, By Drug Type
• 5.2. Branded
  • 5.2.1. Key Market Trends, Growth Factors and Opportunities
  • 5.2.2. Market Size and Forecast, By Region
  • 5.2.3. Market Share Analysis, By Country
• 5.3. Generic
  • 5.3.1. Key Market Trends, Growth Factors and Opportunities
  • 5.3.2. Market Size and Forecast, By Region
  • 5.3.3. Market Share Analysis, By Country

CHAPTER 6: CAPECITABINE MARKET, BY END USER

• 6.1. Market Overview
  • 6.1.1 Market Size and Forecast, By End User
• 6.2. Hospitals
  • 6.2.1. Key Market Trends, Growth Factors and Opportunities
  • 6.2.2. Market Size and Forecast, By Region
  • 6.2.3. Market Share Analysis, By Country
• 6.3. Homecare
  • 6.3.1. Key Market Trends, Growth Factors and Opportunities
  • 6.3.2. Market Size and Forecast, By Region
  • 6.3.3. Market Share Analysis, By Country
• 6.4. Specialty Clinics
  • 6.4.1. Key Market Trends, Growth Factors and Opportunities
  • 6.4.2. Market Size and Forecast, By Region
  • 6.4.3. Market Share Analysis, By Country
• 6.5. Others
  • 6.5.1. Key Market Trends, Growth Factors and Opportunities
  • 6.5.2. Market Size and Forecast, By Region
  • 6.5.3. Market Share Analysis, By Country

CHAPTER 7: CAPECITABINE MARKET, BY REGION

• 7.1. Market Overview
  • 7.1.1 Market Size and Forecast, By Region
• 7.2. North America
  • 7.2.1. Key Market Trends and Opportunities
  • 7.2.2. Market Size and Forecast, By Indication
  • 7.2.3. Market Size and Forecast, By Drug Type
  • 7.2.4. Market Size and Forecast, By End User
  • 7.2.5. Market Size and Forecast, By Country
  • 7.2.6. U.S. Capecitabine Market
    • 7.2.6.1. Market Size and Forecast, By Indication
    • 7.2.6.2. Market Size and Forecast, By Drug Type
    • 7.2.6.3. Market Size and Forecast, By End User
  • 7.2.7. Canada Capecitabine Market
    • 7.2.7.1. Market Size and Forecast, By Indication
    • 7.2.7.2. Market Size and Forecast, By Drug Type
    • 7.2.7.3. Market Size and Forecast, By End User
  • 7.2.8. Mexico Capecitabine Market
    • 7.2.8.1. Market Size and Forecast, By Indication
    • 7.2.8.2. Market Size and Forecast, By Drug Type
    • 7.2.8.3. Market Size and Forecast, By End User
• 7.3. Europe
  • 7.3.1. Key Market Trends and Opportunities
  • 7.3.2. Market Size and Forecast, By Indication
  • 7.3.3. Market Size and Forecast, By Drug Type
  • 7.3.4. Market Size and Forecast, By End User
  • 7.3.5. Market Size and Forecast, By Country
  • 7.3.6. Germany Capecitabine Market
    • 7.3.6.1. Market Size and Forecast, By Indication
    • 7.3.6.2. Market Size and Forecast, By Drug Type
    • 7.3.6.3. Market Size and Forecast, By End User
  • 7.3.7. France Capecitabine Market
    • 7.3.7.1. Market Size and Forecast, By Indication
    • 7.3.7.2. Market Size and Forecast, By Drug Type
    • 7.3.7.3. Market Size and Forecast, By End User
  • 7.3.8. UK Capecitabine Market
    • 7.3.8.1. Market Size and Forecast, By Indication
    • 7.3.8.2. Market Size and Forecast, By Drug Type
    • 7.3.8.3. Market Size and Forecast, By End User
  • 7.3.9. Italy Capecitabine Market
    • 7.3.9.1. Market Size and Forecast, By Indication
    • 7.3.9.2. Market Size and Forecast, By Drug Type
    • 7.3.9.3. Market Size and Forecast, By End User
  • 7.3.10. Spain Capecitabine Market
    • 7.3.10.1. Market Size and Forecast, By Indication
    • 7.3.10.2. Market Size and Forecast, By Drug Type
    • 7.3.10.3. Market Size and Forecast, By End User
  • 7.3.11. Rest of Europe Capecitabine Market
    • 7.3.11.1. Market Size and Forecast, By Indication
    • 7.3.11.2. Market Size and Forecast, By Drug Type
    • 7.3.11.3. Market Size and Forecast, By End User
• 7.4. Asia-Pacific
  • 7.4.1. Key Market Trends and Opportunities
  • 7.4.2. Market Size and Forecast, By Indication
  • 7.4.3. Market Size and Forecast, By Drug Type
  • 7.4.4. Market Size and Forecast, By End User
  • 7.4.5. Market Size and Forecast, By Country
  • 7.4.6. Japan Capecitabine Market
    • 7.4.6.1. Market Size and Forecast, By Indication
    • 7.4.6.2. Market Size and Forecast, By Drug Type
    • 7.4.6.3. Market Size and Forecast, By End User
  • 7.4.7. China Capecitabine Market
    • 7.4.7.1. Market Size and Forecast, By Indication
    • 7.4.7.2. Market Size and Forecast, By Drug Type
    • 7.4.7.3. Market Size and Forecast, By End User
  • 7.4.8. Australia Capecitabine Market
    • 7.4.8.1. Market Size and Forecast, By Indication
    • 7.4.8.2. Market Size and Forecast, By Drug Type
    • 7.4.8.3. Market Size and Forecast, By End User
  • 7.4.9. India Capecitabine Market
    • 7.4.9.1. Market Size and Forecast, By Indication
    • 7.4.9.2. Market Size and Forecast, By Drug Type
    • 7.4.9.3. Market Size and Forecast, By End User
  • 7.4.10. South Korea Capecitabine Market
    • 7.4.10.1. Market Size and Forecast, By Indication
    • 7.4.10.2. Market Size and Forecast, By Drug Type
    • 7.4.10.3. Market Size and Forecast, By End User
  • 7.4.11. Rest of Asia-Pacific Capecitabine Market
    • 7.4.11.1. Market Size and Forecast, By Indication
    • 7.4.11.2. Market Size and Forecast, By Drug Type
    • 7.4.11.3. Market Size and Forecast, By End User
• 7.5. LAMEA
  • 7.5.1. Key Market Trends and Opportunities
  • 7.5.2. Market Size and Forecast, By Indication
  • 7.5.3. Market Size and Forecast, By Drug Type
  • 7.5.4. Market Size and Forecast, By End User
  • 7.5.5. Market Size and Forecast, By Country
  • 7.5.6. Brazil Capecitabine Market
    • 7.5.6.1. Market Size and Forecast, By Indication
    • 7.5.6.2. Market Size and Forecast, By Drug Type
    • 7.5.6.3. Market Size and Forecast, By End User
  • 7.5.7. Saudi Arabia Capecitabine Market
    • 7.5.7.1. Market Size and Forecast, By Indication
    • 7.5.7.2. Market Size and Forecast, By Drug Type
    • 7.5.7.3. Market Size and Forecast, By End User
  • 7.5.8. South Africa Capecitabine Market
    • 7.5.8.1. Market Size and Forecast, By Indication
    • 7.5.8.2. Market Size and Forecast, By Drug Type
    • 7.5.8.3. Market Size and Forecast, By End User
  • 7.5.9. Rest of LAMEA Capecitabine Market
    • 7.5.9.1. Market Size and Forecast, By Indication
    • 7.5.9.2. Market Size and Forecast, By Drug Type
    • 7.5.9.3. Market Size and Forecast, By End User

CHAPTER 8: COMPETITIVE LANDSCAPE

• 8.1. Introduction
• 8.2. Top Winning Strategies
• 8.3. Product Mapping of Top 10 Player
• 8.4. Competitive Dashboard
• 8.5. Competitive Heatmap
• 8.6. Top Player Positioning, 2023

CHAPTER 9: COMPANY PROFILES

• 9.1. F. Hoffmann-La Roche Ltd.
  • 9.1.1. Company Overview
  • 9.1.2. Key Executives
  • 9.1.3. Company Snapshot
  • 9.1.4. Operating Business Segments
  • 9.1.5. Product Portfolio
  • 9.1.6. Business Performance
  • 9.1.7. Key Strategic Moves and Developments
• 9.2. Mylan N.V.
  • 9.2.1. Company Overview
  • 9.2.2. Key Executives
  • 9.2.3. Company Snapshot
  • 9.2.4. Operating Business Segments
  • 9.2.5. Product Portfolio
  • 9.2.6. Business Performance
  • 9.2.7. Key Strategic Moves and Developments
• 9.3. Teva Pharmaceutical Industries Ltd.
  • 9.3.1. Company Overview
  • 9.3.2. Key Executives
  • 9.3.3. Company Snapshot
  • 9.3.4. Operating Business Segments
  • 9.3.5. Product Portfolio
  • 9.3.6. Business Performance
  • 9.3.7. Key Strategic Moves and Developments
• 9.4. Sanofi
  • 9.4.1. Company Overview
  • 9.4.2. Key Executives
  • 9.4.3. Company Snapshot
  • 9.4.4. Operating Business Segments
  • 9.4.5. Product Portfolio
  • 9.4.6. Business Performance
  • 9.4.7. Key Strategic Moves and Developments
• 9.5. Pfizer Inc.
  • 9.5.1. Company Overview
  • 9.5.2. Key Executives
  • 9.5.3. Company Snapshot
  • 9.5.4. Operating Business Segments
  • 9.5.5. Product Portfolio
  • 9.5.6. Business Performance
  • 9.5.7. Key Strategic Moves and Developments
• 9.6. Dr. Reddy's Laboratories Ltd.
  • 9.6.1. Company Overview
  • 9.6.2. Key Executives
  • 9.6.3. Company Snapshot
  • 9.6.4. Operating Business Segments
  • 9.6.5. Product Portfolio
  • 9.6.6. Business Performance
  • 9.6.7. Key Strategic Moves and Developments
• 9.7. Novartis AG
  • 9.7.1. Company Overview
  • 9.7.2. Key Executives
  • 9.7.3. Company Snapshot
  • 9.7.4. Operating Business Segments
  • 9.7.5. Product Portfolio
  • 9.7.6. Business Performance
  • 9.7.7. Key Strategic Moves and Developments
• 9.8. Bayer AG
  • 9.8.1. Company Overview
  • 9.8.2. Key Executives
  • 9.8.3. Company Snapshot
  • 9.8.4. Operating Business Segments
  • 9.8.5. Product Portfolio
  • 9.8.6. Business Performance
  • 9.8.7. Key Strategic Moves and Developments
• 9.9. Eli Lilly And Company.
  • 9.9.1. Company Overview
  • 9.9.2. Key Executives
  • 9.9.3. Company Snapshot
  • 9.9.4. Operating Business Segments
  • 9.9.5. Product Portfolio
  • 9.9.6. Business Performance
  • 9.9.7. Key Strategic Moves and Developments
• 9.10. Merck And Co., Inc.
  • 9.10.1. Company Overview
  • 9.10.2. Key Executives
  • 9.10.3. Company Snapshot
  • 9.10.4. Operating Business Segments
  • 9.10.5. Product Portfolio
  • 9.10.6. Business Performance
  • 9.10.7. Key Strategic Moves and Developments

관련자료